Expert opinions on mCRPC management
Topics in mCRPC management: Unmet needs, guidelines, clinical trials
“The complexity [of mCRPC] requires multidisciplinary care,” says Neal Shore. When should germline testing be considered? How can PSMA PET imaging be effectively integrated into clinical decision-making? Watch as leading experts explore key challenges in access, workflow inefficiencies, and the evolving role of imaging and genetic testing in mCRPC management. View transcript.
Can investigational therapies enable mCRPC treatment in an “all-comer” patient population? Axel Merseburger (University Hospital Schleswig-Holstein, Campus Lübeck, Germany) reflects on this and other possibilities. View transcript.
Axel Merseburger discusses some key challenges in following clinical practice guideline recommendations for mCRPC management, and why guideline uptake remains low. View transcript.
Neeraj Agarwal (Huntsman Cancer Institute, University of Utah, USA) identifies an important caveat for patient populations in phase 3 first-line mCRPC trials, which he considers “the single most debated point” at conferences. View transcript.
Neeraj Agarwal describes similarities and differences in the design of the MAGNITUDE, TALAPRO-2, and PROpel mCRPC trials, noting all trials were “inherently different” and their similarities stop after three common features. View transcript.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.